<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心签名</title><link/>https://pubed.nlm.nlm.nlm.gov/rss-feed/?feed_id=1Vuepj4z_tesaaxkwjxbogotaab-nvu800krrcpq8ylq-rcpq8ylq-＆utm_campaign-2&amp;utmedium-utmedium FC = 2023070814047＆utm_source = Chrome＆ff = 20250309141108＆utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8<description>心血管高分期刊：Pubed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;ff=20250309141108&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> enthing</language><lastbuilddate>太阳，2025年3月9日18:11:09 +0</lastbuilddate><pubDate> Sat, 08 Mar 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title> Corv-A野生考拉的转录沉默的演变</title><link/>https://pubed.ncbi.nlm.nlm.gov/40056902/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>考拉逆转录病毒-A（KORV-A）在北到南波中通过考拉弹出，同时转导生殖系，将遗传基因组修改为过渡到末端逆转录病毒。以前，我们发现KRV-A在种系中表达，但是未填充的基因组转录本被处理为有感觉链PIWI-PIWI-PIWI-PIWI-PIWI-RNA（PINAS），该RNA（PINAS）可能会提供转录后SILNScription的nnial“先天”形式。在这里，我们表明最初的转录后响应。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>2025年2月26日：S0092-8674（25）0 doi：10.1016/j.cell.2025.0在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">考拉逆转录病毒-A（KORV-A）在北到南波中通过考拉弹出，同时转导生殖系，将遗传基因组修改为过渡到末端逆转录病毒。以前，我们发现KRV-A在种系中表达，但是未填充的基因组转录本被处理为有感觉链PIWI-PIWI-PIWI-PIWI-PIWI-RNA（PINAS），该RNA（PINAS）可能会提供转录后SILNScription的nnial“先天”形式。在这里，我们表明，这种最初的转录后反应在布里斯班河以南普遍存在，在该河中表达的Krriv-A被抑制了，启动子是方法，在河流的亚种群中，Pirrans同样丰富。 MAP4K4基因的3&#39;UTR中有多少动物，该动物正在通过北部的北部散布，并产生混合转录本，这些转录本被加工到Ansense Pirnas中，这些杂种引导了转录的sillencing。我们指出，这是这种概率触发了KRV-A的自适应转录幅度，并且对固定很甜蜜。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40056902/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40056902</a> | doi： <a href=https://doi.org/10.1016/j.cell.2025.02.006>10.1016/j.cell.2025.0</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Sat, 08 Mar 2025 06:00:00 -0500</pubDate><dc:creator>坦率</dc:creator><dc:creator>Michaela BJ Blyton</dc:creator><dc:creator>乳白色Abajorga</dc:creator><dc:creator> Birit S Koppetsch</dc:creator><dc:creator>萨曼莎·何</dc:creator><dc:creator>Bo Xu</dc:creator><dc:creator>宗族胡</dc:creator><dc:creator>杰里米·卢本（Jeremy Luban）</dc:creator><dc:creator>基思·查佩尔（Keith Chappell）</dc:creator><dc:creator> Zhiping声音</dc:creator><dc:creator>William E Theurka​​uf</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>细胞</dc:source><dc:title>Corv-A野生考拉的转录沉默的演变</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1016/j.2025.0</dc:identifier></item><item><title>饮食植物小分子的功能多样性通过肠道微型分子</title><link/>https://pubmed.nlm.nih.gov/40056901/?utm_source = chrome＆utm_medium = rss＆outm_campaign = pubed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>植物由与人类健康相关的多种二级代谢产物（PSS）组成。肠道是否以及如何微观供电的PSM的社交ikact被理解不足。在这里，我们表明，离散的饮食和药用电话Phalec糖苷（大量与健康相关的PSM）被人类肠道微che的成员使用。在细菌中，西方人类肠道的主要革兰氏阴性细菌，我们揭示了一种专门的多酶系统。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>2025年2月28日：S0092-8674（25）0155-2 doi：10.1016/j.cell.2025.01.0在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">植物由与人类健康相关的多种二级代谢产物（PSS）组成。肠道是否以及如何微观供电的PSM的社交ikact被理解不足。在这里，我们表明，离散的饮食和药用电话Phalec糖苷（大量与健康相关的PSM）被人类肠道微che的成员使用。在细菌剂中，西方人类肠道的主要革兰氏阴性细菌，我们获得了一种专门的多酶系统，该系统专门用于基于酚类部分的结构差异来处理脱糖苷。这种菌核化代谢系统化学分解了多种生物学功能，将其作为对肠道抗胆汁剂的抗性性抗性性的抗性性，多丁蛋白向高脂蛋白的多丁素的芳族微生物激活。盐酸盐盐盐酸酯盐。总之，我们的结果表明，通过独特的肠道微粒编码的PSM加工系统，苯酚aglamcone“效应剂”功能的生物多样性产生。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40056901/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40056901</a> | doi： <a href=https://doi.org/10.1016/j.cell.2025.01.045>10.1016/j.cell.2025.0</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Sat, 08 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Gavin A Kuziel</dc:creator><dc:creator> Gabriel L Lozano</dc:creator><dc:creator> Corina Simian</dc:creator><dc:creator>长李</dc:creator><dc:creator>约翰·曼尼昂</dc:creator><dc:creator>Emmanuel Stephen-Victor</dc:creator><dc:creator> Talal Chatila</dc:creator><dc:creator> Min Dongong</dc:creator><dc:creator>王王</dc:creator><dc:creator>塞思·拉科夫·纳胡姆（Seth Rakoff-Nahoum）</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>细胞</dc:source><dc:title>饮食植物小分子的功能多样性通过肠道微型分子</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1016/j.2025.0</dc:identifier></item><item><title>斑块侵蚀风险和JAK2 V617F变体</title><link/>https://pubed.ncbi.nlm.nlm.gov/40053703/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>结论：JAK2 V617F遭受高侵蚀风险，并增强中性粒细胞的激活有助于这种侵蚀。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月7日：EHAF1 doi：10.1093/eurheartj/ehaf1在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：不确定潜力（CHIP）的克隆止血作用可以增加心肌梗塞（MI）的风险。在Vararus芯片突变中，JAK2 V617F显着升高了这种风险。然而，JAK2 V617F与我们的两种机制之间的特定关联，斑块侵蚀和斑块破裂尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHS：病例对照研究研究了这些关联。我们中心包括728例侵蚀病例，919例破裂病例和804个对照。对这些个体进行了数字吸收聚合酶链反应，以识别JAK2 V6的存在以前的实验工作已将中性粒细胞暗示在这种突变存在下侵蚀的发病机理中。因此，进行了来自JAK2 V617F载体和健康供体的中性粒细胞的单细胞RNA测序，以寻求负责与JAK22 V6相关的侵蚀的潜在机制</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在参与者中，有26名（3.57％）侵蚀患者，7（.76％）破裂患者和3（.37％）对照对照组为JAK2 V6侵蚀性患者中的载体表现出高血小板计数，血红蛋白和血脂水平较低。逻辑回归分析（将侵蚀或破裂视为单独的情况）表明，vaf≥1％的JAK2 V617F载体显示出与ERISION的签名剂相关[优势比（OR）16.246，95％置信度（CI） &lt;.0001]，但没有破裂（或1.677，95％CI .379-7.415，p = .495）。单细胞RNA序列数据表明，来自JAK2 V617F载体的中性粒细胞显示出与激活，粘附，迁移和Granle分泌相关的基因和基因集的表达水平。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：JAK2 V617F的侵蚀风险很高，并且增强中性粒细胞的激活有助于这种侵蚀。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40053703/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40053703</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf114>10.1093/eurheartj/ehaf1</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Shengfang Wang</dc:creator><dc:creator> Xing Luo</dc:creator><dc:creator>胡</dc:creator><dc:creator>Chen Zhao</dc:creator><dc:creator> Qianhui Sun</dc:creator><dc:creator>明Zeng</dc:creator><dc:creator>小宝</dc:creator><dc:creator>Yini Wang</dc:creator><dc:creator> fangfang Wu</dc:creator><dc:creator> Yeqiu Yang</dc:creator><dc:creator> ying lv</dc:creator><dc:creator> Xiaoxuan bai</dc:creator><dc:creator> Wei Hao</dc:creator><dc:creator> Minghao Liu</dc:creator><dc:creator> boling yi</dc:creator><dc:creator> Yuwu下巴</dc:creator><dc:creator>魏门</dc:creator><dc:creator>Ji li li</dc:creator><dc:creator>李</dc:creator><dc:creator>姜黄金</dc:creator><dc:creator>天吴武</dc:creator><dc:creator>Yipin Zhao</dc:creator><dc:creator>张张</dc:creator><dc:creator>仁安</dc:creator><dc:creator>彼得·利比</dc:creator><dc:creator>Haibo Jia</dc:creator><dc:creator> Bo Yu</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>斑块侵蚀风险和JAK2 V617F变体</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf1</dc:identifier></item><item><title>性别特异性关联和循环蛋白质中的梗塞：潜在的因果关系</title><link/>https://pubed.ncbi.nlm.nlm.gov/40053702/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>如果抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月7日：EHAF1 doi：10.1093/eurheartj/ehaf1在线印刷。</p><p><b>如果抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40053702/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40053702</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf111>10.1093/eurheartj/ehaf1</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Yi Xu</dc:creator><dc:creator>天普冯</dc:creator><dc:creator>Yuanyuan Huang</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>性别特异性关联和循环蛋白质中的梗塞：潜在的因果关系</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf1</dc:identifier></item><item><title>一种新型的经皮技术，用于闭合肺动脉静脉动脉的异常左冠状动脉起源</title><link/>https://pubmed.nlm.nih.gov/40053696/?utm_source=Chrome&amp;utm_medium = rsss＆outm_campaign = pubed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>如果抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月7日：EHAF0 doi：10.1093/eurheartj/ehaf0在线印刷。</p><p><b>如果抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40053696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40053696</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf090>10.1093/eurheartj/ehaf0</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Shubo歌曲</dc:creator><dc:creator>Liyun Zhao</dc:creator><dc:creator> Taibing粉丝</dc:creator><dc:date>2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>一种新型的经皮技术，用于闭合肺动脉静脉动脉的异常左冠状动脉起源</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf0</dc:identifier></item><item><title>循环蛋白质和事件的心肌梗塞：评估性别特定的差异和因果关系</title><link/>https://pubmed.nlm.nih.gov/40053693/?utm_source = chrome＆utm_medium = rss＆outm_campaign = pubed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>如果抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月7日：EHAF1 doi：10.1093/eurheartj/ehaf1在线印刷。</p><p><b>如果抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40053693/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40053693</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf113>10.1093/eurheartj/ehaf1</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Olga E Titova</dc:creator><dc:creator> Shuai Yuan</dc:creator><dc:creator> Liisa Byberg</dc:creator><dc:creator>约翰男爵。</dc:creator><dc:creator>拉尔斯·林德（Lars Lind）</dc:creator><dc:creator> KarlMichaëlsson</dc:creator><dc:creator> Susanna C Larsson</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>循环蛋白质和事件的心肌梗塞：评估性别特定的差异和因果关系</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf1</dc:identifier></item><item><title>冠状病毒疾病疫苗接种后心血管事件的可能观点</title><link/>https://pubmed.nlm.nih.gov/40053691/?utm_source = chrome&amp;utm_medium = rss＆outm_campaign = pubed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>如果抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月7日：EHAF1 doi：10.1093/eurheartj/ehaf1在线印刷。</p><p><b>如果抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40053691/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40053691</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf112>10.1093/eurheartj/ehaf1</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Xue-Yan Gong</dc:creator><dc:creator>詹姆斯·郑钟魏</dc:creator><dc:creator>张张</dc:creator><dc:date>2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>冠状病毒疾病疫苗接种后心血管事件的可能观点</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf1</dc:identifier></item><item><title>专注于运动员的冠状动脉粥样硬化，非刺激性冠状动脉，急性血管综合征的机制和Marfan综合征的机制</title><link/>https://pubmed.nlm.nih.gov/400533441/?utm_source=Chrome&amp;utm_medium = rsss＆outm_campaign = pubed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>如果抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月7日； 46（10）：877-8 doi：10.1093/eurheartj/ehaf0</p><p><b>如果抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40053441/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40053441</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf055>10.1093/eurheartj/ehaf055</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Filipippo Crea</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>专注于运动员的冠状动脉粥样硬化，非刺激性冠状动脉，急性血管综合征的机制和Marfan综合征的机制</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf0</dc:identifier></item><item><title>推动边界：管理110年患者的未知领域</title><link/>https://pubed.ncbi.nlm.nlm.gov/40052840/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>如果抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月7日：EHAF0 doi：10.1093/eurheartj/ehaf0在线印刷。</p><p><b>如果抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40052840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40052840</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf030>10.1093/eurheartj/ehaf0</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator>安东尼贝叶斯 - 天然</dc:creator><dc:date>2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>推动边界：管理110年患者的未知领域</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf0</dc:identifier></item><item><title>促进南亚和东南亚的公平健康寿命</title><link/>https://pubed.nlm.nlm.nlm.gov/4052839/?utm_source=Chrome&amp;utm_medium = rsss＆outm_campaign = pubaign = pubbed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>如果抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月7日：EHAF0 doi：10.1093/eurheartj/ehaf0在线印刷。</p><p><b>如果抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40052839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40052839</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf051>10.1093/eurheartj/ehaf0</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Raaj Kishore Biswas</dc:creator><dc:creator>尼古拉斯·科梅尔（Nicholas Koemel）</dc:creator><dc:creator> Luigi Fontana</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>促进南亚和东南亚的公平健康寿命</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf0</dc:identifier></item><item><title>欧洲心脏肿瘤学会委员会的更新</title><link/>https://pubed.ncbi.nlm.nlm.gov/4052835/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>如果抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月7日：EHAF0 doi：10.1093/eurheartj/ehaf0在线印刷。</p><p><b>如果抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40052835/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40052835</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf052>10.1093/eurheartj/ehaf0</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator> TeresaLópez-Fernández</dc:creator><dc:creator>彼得·范·德·梅尔·梅尔</dc:creator><dc:creator>亚历山大·里昂</dc:creator><dc:date>2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>欧洲心脏肿瘤学会委员会的更新</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf0</dc:identifier></item><item><title> SGLT2抑制剂：不适合高血压，而是在高血压中非常适当</title><link/>https://pubed.ncbi.nlm.nlm.gov/40052832/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>如果抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月7日：Ehae7 doi：10.1093/eurheartj/ehae7在线印刷。</p><p><b>如果抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40052832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40052832</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehae751>10.1093/eurheartj/ehae7</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator>弗朗兹·H·梅塞利利（Franz H Messerlili）</dc:creator><dc:creator>肾脏的Schoenenberger-Berzins</dc:creator><dc:creator>米歇尔·伯尼尔（Michel Burnier）</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>SGLT2抑制剂：不适合高血压，而是在高血压中非常适当</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehae7</dc:identifier></item><item><title>心脏移植中的临床结果与正常热脉冲器官灌注：OCS心脏灌注注册表的报告</title><link/>https://pubed.ncbi.nlm.nlm.gov/40052272/?utm_source = chrome&amp;utm_medium = rsss＆outm_campaign = pubaign = pubbed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>结论：我们证明，对DBD捐赠者的OCS实施（主要使用专用恢复团队）与扩展的供体标准，更长的运输距离和出色的后置式后结果有关。在OCS-DCD供体中，结果与NRP-DCD恢复的捐赠者的结果平行，并与DBD供体器官进行比较。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>2025年3月7日DOI：10.1161/CirculationAha.124.0在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：一种保存系统，器官护理系统（OCS； Transmmedics）在器官传输过程中使用正常的热脉冲灌注进行心脏移植。该系统在脑死亡后（DBD）和循环死亡（DCD）后从扩展的标准供体（DBD）中恢复的心脏中表现出了有利的结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：OCS心脏灌注注册表使用OCS，静态冷藏（SC）或从DCD供体中恢复的OCS，静态冷藏（SCS）或胸腔正常热区域灌注（NRP）收集有关美国心脏移植的数据。与来自DCD供体的SCS心脏和OCS心脏相比，我们分析了用OCS供体心脏（DBD或DCD）移植的患者（DBD或DCD）的患者中的供体和受体特征和移植后结果。倾向得分匹配用于生存分析以调整受体特征之间的差异。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在2021年至2023年之间，在心脏灌注注册表中分析了从56个中心招募的3225个心脏移植。 OCS在3225次心脏移植中的854中使用（26.4％），其中340（39.8％）我们DBD和514（60.2％）是DCD供体，而2174 DBD捐助者和肢体我们的捐助者和肢体我们的捐助者和肢体我们捐助我们的捐助者我们回复我们回顾我们我们的回忆我们我们的回复者我们是我们的回复者。使用NRP技术。 OCS-DBD组GRAAT数量数量的器官数量的器官数量在最终接受之前<i>拒绝</i>（13对6； Wilcoxon Rank Sum， <i>P</i> &lt;0.001）和Logger Transport距离（667英里对&lt;0 SCS-DBD。 12个月的生存率为2组（OCS-DBD为89.9％，而SCS-DBD为90.6％；边际COX模型， <i>P</i> = 0.54）。在OCS-DCD和SCS-DBD组中，在12个月时的存活率也Simlar（分别为91.0％和92.5％；边缘COX模型， <i>P</i> = 0.32）。 OCS-DCD和NRP-DCD组表现出相似的生存率（分别为91.0％和91.7％；日志等级， <i>p</i> = 0.63），尽管与DCD相比，OCS-DCD中的运输失败失败了。 223<i>英里</i>；到2023年，所有OCS捐赠者管理和恢复的90％是由专用器官恢复团队进行的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们证明，对DBD捐赠者的OCS实施（主要使用专用恢复团队）与扩展的供体标准，更长的运输距离和出色的后置式后结果有关。在OCS-DCD供体中，结果与NRP-DCD恢复的捐赠者的结果平行，并与DBD供体器官进行比较。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40052272/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40052272</a> | doi： <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071743>10.1161/CirculationAha.124.071743</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator>约瑟夫·斯特里克（Josef Stehlik）</dc:creator><dc:creator> Maryjane a farrr</dc:creator><dc:creator> Mandeep R Mehra</dc:creator><dc:creator> Jacob N Schroder</dc:creator><dc:creator> David D&#39;Alessandro</dc:creator><dc:creator> Jay D Pal Pal</dc:creator><dc:creator> Mauricio Villavicencio</dc:creator><dc:creator>彼得·格伯（Peter J Gruber）</dc:creator><dc:creator> Gregory S Couper</dc:creator><dc:creator> Yasuhiro Snead</dc:creator><dc:creator> Parag C Pattel</dc:creator><dc:creator> PANES DANESMAND</dc:creator><dc:creator> Liviu Klein</dc:creator><dc:creator> Ashish S Shah</dc:creator><dc:creator>埃里克·R船长</dc:creator><dc:creator>Fadad Esmainian</dc:creator><dc:creator>丹尼尔·戈德斯坦</dc:creator><dc:creator>Suguru Ohira</dc:creator><dc:creator>卢西安·洛桑基（Lucian Lozonschi）</dc:creator><dc:creator> David J Kaczorowski</dc:creator><dc:creator>武田小锦鱼</dc:creator><dc:creator>Rajasekekhar Sr Malyala</dc:creator><dc:creator>乔纳森·W哈夫</dc:creator><dc:creator>丹·迈尔（Dan M Meyer）</dc:creator><dc:creator>本杰明·C太阳</dc:creator><dc:creator>Victor Pretorius</dc:creator><dc:creator> Arman吉利克</dc:creator><dc:creator>Anelechi C Annunwu</dc:creator><dc:creator>塞莱斯特·威廉姆斯</dc:creator><dc:creator>duc t pham</dc:creator><dc:creator> Masashi Kai Kai</dc:creator><dc:creator> Nasir Z Sulemanjee</dc:creator><dc:creator>再一次</dc:creator><dc:creator>Masaki Funamoto</dc:creator><dc:creator>克里斯托弗·萨勒诺（Christopher T Salerno）</dc:creator><dc:creator>约翰的偶像</dc:creator><dc:creator>卢西安·达勒姆（Lucian Durham）</dc:creator><dc:creator>安德鲁·谢弗（Andrew Shaffer）</dc:creator><dc:creator> Xhou</dc:creator><dc:creator>法汉·扎法尔（Farhan Zafar）</dc:creator><dc:creator>肖恩·普莱尼（Sean P Pinney）</dc:creator><dc:creator>卡梅尔米兰</dc:creator><dc:date>2025-03-0</dc:date><dc:source>循环</dc:source><dc:title>心脏移植中的临床结果与正常热脉冲器官灌注：OCS心脏灌注注册表的报告</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.071743</dc:identifier></item><item><title>澳大利亚新西兰自发性冠状动脉剖析队列研究：主要不良心血管事件和复发的预测因子</title><link/>https://pubed.ncbi.nlm.nih.gov/4049585/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>结论：这些发现支持该假设的主要是由壁内出血引起的，其有害的抗血小板治疗和抗凝性抗凝性与心血管不良结局的有害关联。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月7日：EHAF0 doi：10.1093/eurheartj/ehaf0在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：自发性冠状动脉动脉解剖（SCAD）是急性冠状动脉综合征（ACS）的越来越多的原因。最近的数据表明，与SCAD后的单一抗衡值相比，双重抗血小板治疗的有害关联。这项研究调查了SCAD患者的主要不良心血管事件（MACE）和复发的独立预测指标。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这项多中心队列研究涉及23个澳大利亚和新西兰地点，该地点因对正确的实验室裁决的SCAD确认，年龄≥18岁的患者增加了ACS。多变量COX比例危害模型分析了主要MACE结果的预测因子。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在586名患者中，有505例（150名前瞻性，355个回顾性），通过核心实验室裁决确认了SCAD，平均年龄为52.2±10.6岁，女性为88.6％，女性为74.5％在长期随访（中位21个月）中，狼牙棒和SCAD复发分别发生在8.6％和3.6％的患者中。排出的口服抗凝[调整后危险比（AHR）3.8，95％置信区间（CI）1.6-9.3，p = =。发育异常（AHSPlasia（AHR 2.2，95％CI 1.05-4.5，p = .037），中风病史（AHR 3.8，95％1.2-12.2，p = .03）与较高的MACE独立相关。纤维肌发育不良（AHR 3.9，95％CI 1.5-26.5，p = .01），Ticaregor与阿司匹林结合（AHR 2.6，95％CI 2.1-5.3，p 1。 = .01）也与较高的可鼠有关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些发现支持该假设的主要是由壁内出血引起的，其有害的抗血小板治疗和抗凝性抗凝性与心血管不良结局的有害关联。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40049585/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">4049585</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf097>10.1093/eurheartj/ehaf0</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator> quan m dang</dc:creator><dc:creator>彼得·J·帕斯蒂斯（Peter J Psaltis）</dc:creator><dc:creator> Sonya Bourgess</dc:creator><dc:creator> Jaya Chandrasecar</dc:creator><dc:creator> Swati Mukhere</dc:creator><dc:creator>伦纳德·克里萨里德斯（Leonard Kritharides）</dc:creator><dc:creator>奈杰尔·杰普森（Nigel Jepson）</dc:creator><dc:creator>莎拉·费尔利（Sarah Fairley）</dc:creator><dc:creator> Abdul Ihdayhid</dc:creator><dc:creator>杰米·拉兰（Jamie Layland）</dc:creator><dc:creator>理查德·塞尔特（Richard Szirt）</dc:creator><dc:creator> Seif El-Jack</dc:creator><dc:creator> Aniket Puri</dc:creator><dc:creator>以斯帖·戴维斯（Esther Davis）</dc:creator><dc:creator> Imran Shiekh</dc:creator><dc:creator>露丝·阿诺德（Ruth Arnold）</dc:creator><dc:creator> Monique Watts</dc:creator><dc:creator>杰西卡（Jessica A Marathe）</dc:creator><dc:creator> Rohan Bhagwandaen</dc:creator><dc:creator> Edwina Wing-Lun</dc:creator><dc:creator> Ravinay Bhindi</dc:creator><dc:creator>汤姆·福特</dc:creator><dc:creator>西德尼·卢（Sidney Lo）</dc:creator><dc:creator>西蒙妮·马希纳（Simone Marschner）</dc:creator><dc:creator>莎拉·扎曼（Sarah Zaman）</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>澳大利亚新西兰自发性冠状动脉剖析队列研究：主要不良心血管事件和复发的预测因子</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf0</dc:identifier></item><item><title> cry-et的copa retrotentoson完整组织的室内结构和快照</title><link/>https://pubed.ncbi.nlm.nih.gov/4049165/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>长时间重复（LTR）反转座子属于转座元素（TES），自主复制的遗传元素，这些遗传元素进入宿主的基因组中。在动物中，果蝇Melanogaster是TE研究的重要模型生物，并包含了几种LTR逆转座子，包括Ty1-Copia家族，这在与相关相关（VLLKET）的进化上是相关的（Vllket）在这项研究中，我们使用以CROO为中心的离子束（FIB）铣削和拔出。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>2025年3月5日：S0092-8674（25）0159-X。 doi：10.1016/j.cell.2025.0在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">长时间重复（LTR）反转座子属于转座元素（TES），自主复制的遗传元素，这些遗传元素进入宿主的基因组中。在动物中，果蝇Melanogaster是TE研究的重要模型生物，并包含了几种LTR逆转座子，包括Ty1-Copia家族，这在与相关相关（VLLKET）的进化上是相关的（Vllket）在这项研究中，我们使用以CROO的离子束（FIB）铣削和提出方法来可视化卵巢细胞和完整的鸡蛋室中的COPI VAP （croyo-et）。尽管细胞质COPI VAPP的大小各不相同，但核VLP是均匀的，形成了否定的包装簇，支持核进口的模型，其中核进口充当大小的SLECTOR。分析缺乏Te抑制的piwiintracting RNA（PIRNA）途径的苍蝇，我们观察到capipia在精子发生过程中的易位到细胞核。我们的发现提供了有关活性LTR逆转录座子的复制周期和细胞结构生物学的见解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40049165/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40049165</a> | doi： <a href=https://doi.org/10.1016/j.cell.2025.02.003>10.1016/j.cell.2025.0</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Sven Clumppe</dc:creator><dc:creator> Kirsten Senti</dc:creator><dc:creator>弗洛里安·贝克（Florian Beck）</dc:creator><dc:creator>珍妮·萨克韦（Jenny Sachweh）</dc:creator><dc:creator>伯恩哈德·汉波尔兹（Bernhard Hampoelz）</dc:creator><dc:creator>保罗·罗奇（Paolo Ronchi）</dc:creator><dc:creator>中提琴</dc:creator><dc:creator>Marlene BrandSteTeTeTete</dc:creator><dc:creator> Assa Yerostlaviz</dc:creator><dc:creator>约翰·布雷格斯（John Breggs）</dc:creator><dc:creator>朱利叶斯·班尼克克（Julius Bnennecke）</dc:creator><dc:creator>马丁·贝克</dc:creator><dc:creator>JürgenM Ptzko</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>细胞</dc:source><dc:title>cry-et的copa retrotentoson完整组织的室内结构和快照</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1016/j.2025.0</dc:identifier></item><item><title> CXCL12驱动各种种群的冠状动脉解剖结构的自然差异</title><link/>https://pubed.ncbi.nlm.nlm.gov/4049164/?utm_source = chrome&amp;utm_medium = rsss＆outm_campaign = pubbed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>冠状动脉具有特定的分支模式，对于氧化心肌至关重要。在人类中，冠状动脉解剖结构在下/后左心的灌注方面存在自然变化，该心脏可以从右拱形树，左或A表型分支，称为冠状动脉优势。使用>; 60,000名美国退伍军人的血管读物数据，我们对全基因组主导地位的冠军协会进行了缩减，从而揭示了中度的遗传力和。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>2025年3月3日：S0092-8674（25）00161-8 doi：10.1016/j.cell.2025.0在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">冠状动脉具有特定的分支模式，对于氧化心肌至关重要。在人类中，冠状动脉解剖结构在下/后左心的灌注方面存在自然变化，该心脏可以从右拱形树，左或A表型分支，称为冠状动脉优势。使用>; 60,000名美国退伍军人的血管造影数据，我们对全基因组主导地位研究缩减了冠状动脉优势研究，揭示了中度的遗传力，并确定了十个签名基因座。最牢固的关联发生在欧洲和非洲 - 委托人队列中的CXCL12附近，下stetam对CXCL12表达的侵蚀分析。我们表明，CXCL12在统治时期是在人类胎儿心脏中表达的。减少小鼠中CXCL12改变了冠状动脉优势，并导致隔膜动脉远离CXCL12表达结构域。多少罚款表明CXCL12模式人类冠状动脉，通过靶向发育途径为“医学血运重建”铺平了道路。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40049164/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40049164</a> | doi： <a href=https://doi.org/10.1016/j.cell.2025.02.005>10.1016/j.cell.2025.0</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Pamela Eos Coronado</dc:creator><dc:creator>斋扬周</dc:creator><dc:creator>小粉丝</dc:creator><dc:creator>Daniela Zanetti</dc:creator><dc:creator>杰弗里（Jeffrey）</dc:creator><dc:creator> Pratala Pratima Pratima</dc:creator><dc:creator> AzaliaMartínezJ​​aimes</dc:creator><dc:creator> Elie N Farah</dc:creator><dc:creator> Soumya Kundu</dc:creator><dc:creator> Salil S Deshpande</dc:creator><dc:creator> Ivy Everreen</dc:creator><dc:creator> Pik Fang Kho</dc:creator><dc:creator> Qixuan MA</dc:creator><dc:creator>奥斯汀·塔·希拉德（Austin T Hillard）</dc:creator><dc:creator>莎拉·阿布拉莫维茨（Sarah Abramowitz）</dc:creator><dc:creator> Saijuuju Pyarajan</dc:creator><dc:creator>丹尼尔·多奇特曼（Daniel Dochtermann）</dc:creator><dc:creator>数百万退伍军人计划</dc:creator><dc:creator>Scot M Damrauer</dc:creator><dc:creator> Kyong-Mi Chang</dc:creator><dc:creator>迈克尔·莱文（Michael G Levin）</dc:creator><dc:creator>弗吉尼亚D温恩</dc:creator><dc:creator>Anca MPaşca</dc:creator><dc:creator>玛丽·普罗蒙顿（Mary Plomondon）</dc:creator><dc:creator>斯蒂芬·沃尔多（Stephen W Waldo）</dc:creator><dc:creator>菲利普·S·托索（Philip S Tsao）</dc:creator><dc:creator> Anshul Kundaje</dc:creator><dc:creator> Neil C Chi</dc:creator><dc:creator> Shoa L Clarke</dc:creator><dc:creator>克里斯蒂红马</dc:creator><dc:creator>Themistocles l Asimeses</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>细胞</dc:source><dc:title>CXCL12驱动各种种群的冠状动脉解剖结构的自然差异</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1016/j.2025.0</dc:identifier></item><item><title>普通和发散的细胞细胞细胞细胞病因在发育不全左心脏综合征和右心脏综合征下</title><link/>https://pubmed.nlm.nih.gov/40486662/?utm_source=Chrome&amp;utm_medium = rsss＆outm_campaign=pubed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>如果抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月6日：EHAF1 doi：10.1093/eurheartj/ehaf1在线印刷。</p><p><b>如果抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40048662/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40486662</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf121>10.1093/eurheartj/ehaf1</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator>杨</dc:creator><dc:creator>Cankun Wang</dc:creator><dc:creator> shiqiao ye</dc:creator><dc:creator>汉娜秦</dc:creator><dc:creator>马修·阿隆佐（Matthew Alonzo）</dc:creator><dc:creator>安吉拉·欧纳特</dc:creator><dc:creator>亚伦·阿尔尔（Aaron Argall）</dc:creator><dc:creator>凯伦·德克萨斯（Karen Texter）</dc:creator><dc:creator>秦马</dc:creator><dc:creator>Vidu Garg</dc:creator><dc:creator>明与赵</dc:creator><dc:date>2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>普通和发散的细胞细胞细胞细胞病因在发育不全左心脏综合征和右心脏综合征下</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf1</dc:identifier></item><item><title>医疗疗法和恢复BCIS2和搅拌的结果：单个患者数据分析</title><link/>https://pubed.ncbi.nlm.nlm.gov/40486661/?utm_source=chrome&amp;utm_medium = rsss＆outm_campaign = pubbed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ-＆FC = 20230814047＆ff = 20250914108＆v = 2<description>结论：在复活的BCIS2接受药物治疗的缺血性心肌病患者进行了更好的结果，并在Orut CABG手术中得到了更好的搅拌。有必要对该人群中BBG，PCI和医疗疗法进行进一步的试验。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 3月6日：EHAF0 doi：10.1093/eurheartj/ehaf0在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：在缺血性心力衰竭试验扩展研究（Stiches）的手术治疗中心室功能障碍试验（恢复B这项研究的目的是探索仅在Stistic vs中仅接受药物治疗治疗的参与者的结果差异。恢复BCIS2并评估鲍格或PCI的增量益处。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">甲基苯丙胺：来自两个多中心随机试验的调整后的参与者数据的汇总分析。所有患者均离开心室射血分数≤35％和冠状动脉疾病，并接受了药物治疗。参与者将1：1随机分配给CABG（Strash）或PCI（Revived-BCIS2）。主要结果是在所有可用随访中全因死亡和住院治疗的综合。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共有1912名参与者（男性为88％，白人种族76％）被包括在98.3％的随访中，以进行主要结果。 Midian随访时间为118个月，在Review-BCIS2中进行了41个月的随访那些单独接受药物治疗的人在复活的BCIS2中接受PCI的患者即使在系统中获得很大的结果也不太可能经历主要结果事件。在搅拌中用CABG治疗的患者治疗的患者的调整结果是鼻子仅接受Revived-BCIS2的药物治疗</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在复活的BCIS2接受药物治疗的缺血性心肌病患者进行了更好的结果，并在Orut CABG手术中得到了更好的搅拌。有必要对该人群中BBG，PCI和医疗疗法进行进一步的试验。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40048661/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40486661</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf080>10.1093/eurheartj/ehaf0</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> PubMed：4</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator>马修·瑞安（Matthew Ryan）</dc:creator><dc:creator>马克·佩特（Mark C Petere）</dc:creator><dc:creator> Evanlos Contolatelis</dc:creator><dc:creator>马修·多德（Matthew Doddd）</dc:creator><dc:creator>广孔</dc:creator><dc:creator>Guillaume Marquis-Gravel</dc:creator><dc:creator> Kieran F Docherty</dc:creator><dc:creator>蒂姆·克莱顿（Tim Clayton）</dc:creator><dc:creator>亚历山德拉·J·兰西（Alexandra J Lansy）</dc:creator><dc:creator>妈妈妈妈</dc:creator><dc:creator>让·卢西安·鲁劳（Jean-Lucien Rouleau）</dc:creator><dc:creator> Eric J Velazquez</dc:creator><dc:creator> Divaka Perera</dc:creator><dc:date> 2025-03-0</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>医疗疗法和恢复BCIS2和搅拌的结果：单个患者数据分析</dc:title><dc:identifier>PMID：4</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf0</dc:identifier></item><item><title> SLC31A1损失耗尽线粒体铜并促进心脏纤维化</title><link/>https://pubmed.nlm.nih.gov/40486600/?utm_source = chrome＆utm_medium = rss＆outm_campaign = pubbed-2&amp;utm_content = 1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250309141108&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: A novel epigenetic mechanism was demonstrated through which copper deficiency increases mitochondrial copper depletion and impairs CF. Findings provide new insights for the development of preventive measures for CF. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Mar 6:ehaf130. doi: 10.1093/eurheartj/ehaf130. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Metals serve as co-factors for a host of metalloenzymes involved in mitochondrial metabolic reprogramming. Modifications in metal homeostasis are linked to epigenetic mechanisms. However, the epigenetic mechanisms through which metal affects cardiac fibrosis (CF) remain poorly understood. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The metal content of mouse heart samples was measured using inductively coupled plasma mass spectrometry. Cardiac fibroblast-specific MeCP2-deficient mice and control mice were treated with isoprenaline/angiotensin II to induce CF. AAV9 carrying POSTN promoter-driven small hairpin RNA targeting MeCP2, YTHDF1, or SLC31A1 and the copper-chelating agent tetrathiomolybdate were administered to investigate their vital roles in CF. Histological and biochemical analyses were performed to determine how YTHDF1/MeCP2 regulated SLC31A1 expression in CF. The reconstitution of SLC31A1 in YTHDF1/MeCP2-deficient cardiac fibroblasts and mouse hearts was performed to study its effect on mitochondrial copper depletion and fibrosis. Human heart tissues from atrial fibrillation patients were used to validate the findings. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Lower copper concentrations are accompanied by SLC31A1 down-regulation and mitochondrial copper depletion in CF. Fibroblast-specific SLC31A1 deficiency enhances mitochondrial copper depletion, augments glycolysis, promotes fibroblast proliferation and triggers CF. SLC31A1 inhibition due to increased MeCP2-recognized methylating CpG islands of SLC31A1 in the promoter region restrains its transcription. Conversely, MeCP2 knockdown rescued SLC31A1 expression, resulting in contradictory effects. MeCP2 up-regulation is associated with elevated m6A mRNA levels. Mechanistically, YTHDF1 recognizes target MeCP2 mRNA and induces its translation. In human heart tissues from atrial fibrillation patients, reduced copper concentrations and SLC31A1 expression, along with elevated levels of YTHDF1 and MeCP2, were observed. These changes were associated with mitochondrial copper depletion, enhanced glycolysis, and CF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: A novel epigenetic mechanism was demonstrated through which copper deficiency increases mitochondrial copper depletion and impairs CF. Findings provide new insights for the development of preventive measures for CF.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40048660/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40048660</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf130>10.1093/eurheartj/ehaf130</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> pubmed:40048660</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Bin Tu</dc:creator><dc:creator> Kai Song</dc:creator><dc:creator> Ze-Yu Zhou</dc:creator><dc:creator> Li-Chan Lin</dc:creator><dc:creator> Zhi-Yan Liu</dc:creator><dc:creator> He Sun</dc:creator><dc:creator> Yang Zhou</dc:creator><dc:creator> Ji-Ming Sha</dc:creator><dc:creator> Yan Shi</dc:creator><dc:creator> Jing-Jing Yang</dc:creator><dc:creator> Ye Zhang</dc:creator><dc:creator> Jian-Yuan Zhao</dc:creator><dc:creator> Hui Tao</dc:creator><dc:date> 2025-03-06</dc:date><dc:source> European heart journal</dc:source><dc:title> SLC31A1 loss depletes mitochondrial copper and promotes cardiac fibrosis</dc:title><dc:identifier> pmid:40048660</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf130</dc:identifier></item><item><title> Missing &#39;lncs&#39;: how insufficient scrutiny can lead to misrepresentation of long non-coding RNAs (lncRNAs) and their function in cardiovascular disease</title><link/> https://pubmed.ncbi.nlm.nih.gov/40048659/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250309141108&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Mar 6:ehaf115. doi: 10.1093/eurheartj/ehaf115. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40048659/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40048659</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf115>10.1093/eurheartj/ehaf115</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> pubmed:40048659</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Matthew Bennett</dc:creator><dc:creator> Igor Ulitsky</dc:creator><dc:creator> Andrew H Baker</dc:creator><dc:date> 2025-03-06</dc:date><dc:source> European heart journal</dc:source><dc:title> Missing &#39;lncs&#39;: how insufficient scrutiny can lead to misrepresentation of long non-coding RNAs (lncRNAs) and their function in cardiovascular disease</dc:title><dc:identifier> pmid:40048659</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf115</dc:identifier></item><item><title> LncRNA MIR181A1HG Deficiency Attenuates Vascular Inflammation and Atherosclerosis</title><link/> https://pubmed.ncbi.nlm.nih.gov/40047069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250309141108&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: These findings identify MIR181A1HG as a central driver of vascular inflammation in atherosclerosis by its ability to decoy Foxp1 away from target gene promoters and activate NLRP3 inflammasome in the vascular endothelium. Our study suggests MIR181A1HG as a future therapeutic target for vascular inflammatory disease states. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2025 Mar 6. doi: 10.1161/CIRCRESAHA.124.325196. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Endothelial cell (EC) dysfunction and vascular inflammation are critical in the initiation and progression of atherosclerosis. Long noncoding RNAs play a critical role in vascular pathology, but relatively little is known about their involvement in controlling vascular inflammation. MIR181A1HG is a conserved long noncoding RNA located in juxtaposition with miR-181a1 and miR-181b1, both involved in vascular inflammation. The study aims to investigate the role of MIR181A1HG in regulating vascular inflammation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We examined the expression of MIR181A1HG in both human and mouse atherosclerotic lesions. Loss-of-function and gain-of-function studies, and multiple RNA-protein interaction assays were used to investigate the role and molecular mechanisms of MIR181A1HG in vascular inflammation and atherosclerosis. The atherosclerotic phenotypes of MIR181A1HG <sup>-/-</sup> ApoE <sup>-/-</sup> mice were analyzed in combination with single-cell RNA sequencing. The transcriptional regulation of MIR181A1HG was verified through luciferase reporter and chromatin immunoprecipitation assays. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: MIR181A1HG expression was abundant in ECs and significantly increased in both human and mouse atherosclerotic lesions. MIR181A1HG <sup>-/-</sup> ApoE <sup>-/-</sup> mice had reduced NLRP (NLR family pyrin domain containing) 3 inflammasome signaling, EC activation, monocyte infiltration, and atherosclerotic lesion formation. Genetic deletion of MIR181A1HG in myeloid sells did not alter the progression of atherosclerosis. Single-cell RNA sequencing analysis revealed that MIR181A1HG deficiency reduced the proportion of immune cells and enriched anti-inflammation pathways in EC clusters in atherosclerotic lesions. In contrast, EC-specific MIR181A1HG overexpression promoted NLRP3 inflammasome signaling, EC activation, and atherosclerotic lesion formation, effects that were reversed by pharmacological inhibition of NLRP3 (MCC950). MIR181A1HG was transcriptionally activated via an NF-κB (nuclear factor kappa B)/p65-dependent pathway. Mechanistically, MIR181A1HG mediated these effects on regulating NLRP3 inflammasome and EC activation in part through decoying Foxp1 (forkhead box transcription factor 1) away from the promoters of target genes, which was independent of the miR-181a1/b1 cluster. Finally, EC-specific Foxp1 silencing reversed the antiatherosclerotic effect mediated by MIR181A1HG-deletion in vivo. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: These findings identify MIR181A1HG as a central driver of vascular inflammation in atherosclerosis by its ability to decoy Foxp1 away from target gene promoters and activate NLRP3 inflammasome in the vascular endothelium. Our study suggests MIR181A1HG as a future therapeutic target for vascular inflammatory disease states.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40047069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250309141108&v=2.18.0.post9+e462414">40047069</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.124.325196>10.1161/CIRCRESAHA.124.325196</a></p></div> ]]]]]</content:encoded><guid ispermalink="false"> pubmed:40047069</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Huaner Ni</dc:creator><dc:creator> Yulong Ge</dc:creator><dc:creator> Ying Zhuge</dc:creator><dc:creator> Xiaoqiang Liu</dc:creator><dc:creator> Hangwei Chen</dc:creator><dc:creator> Junyi Liu</dc:creator><dc:creator> Weifeng Li</dc:creator><dc:creator> Xiang Wang</dc:creator><dc:creator> Gu Shen</dc:creator><dc:creator> Qiuling Wang</dc:creator><dc:creator> Rulin Zhuang</dc:creator><dc:creator> Mark W Feinberg</dc:creator><dc:creator> Fang Wang</dc:creator><dc:date> 2025-03-06</dc:date><dc:source> Circulation research</dc:source><dc:title> LncRNA MIR181A1HG Deficiency Attenuates Vascular Inflammation and Atherosclerosis</dc:title><dc:identifier> pmid:40047069</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.124.325196</dc:identifier></item></channel></rss>